NASDAQ:SLP

Simulations Plus Stock Forecast, Price & News

$47.68
-0.20 (-0.42 %)
(As of 07/23/2021 11:13 AM ET)
Add
Compare
Today's Range
$47.19
$47.68
50-Day Range
$43.37
$56.00
52-Week Range
$42.02
$90.92
Volume1,534 shs
Average Volume187,144 shs
Market Capitalization$959.80 million
P/E Ratio85.14
Dividend Yield0.51%
Beta-0.07
30 days | 90 days | 365 days | Advanced Chart
Receive SLP News and Ratings via Email

Sign-up to receive the latest news and ratings for Simulations Plus and its competitors with MarketBeat's FREE daily newsletter.


Simulations Plus logo

About Simulations Plus

Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.

Headlines

Analyzing Simulations Pluss Ex-Dividend Date
Analyzing Simulations Plus's Ex-Dividend Date
July 22, 2021 |  benzinga.com
Simulations Plus (NASDAQ:SLP) Sets New 12-Month Low at $42.30
Simulations Plus (NASDAQ:SLP) Sets New 12-Month Low at $42.30
July 19, 2021 |  americanbankingnews.com
Simulations Plus (NASDAQ:SLP) Price Target Cut to $65.00
Simulations Plus (NASDAQ:SLP) Price Target Cut to $65.00
July 13, 2021 |  americanbankingnews.com
Heres Why Simulations Plus Stock Is Sliding Today
Here's Why Simulations Plus Stock Is Sliding Today
July 13, 2021 |  finance.yahoo.com
Simulations Plus (NASDAQ:SLP) PT Lowered to $54.00
Simulations Plus (NASDAQ:SLP) PT Lowered to $54.00
July 13, 2021 |  americanbankingnews.com
Simulations Plus: Q3 Earnings Insights
Simulations Plus: Q3 Earnings Insights
July 12, 2021 |  benzinga.com
7,174
7,174
July 12, 2021 |  businesswire.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.07 out of 5 stars

Computer And Technology Sector

69th out of 1,647 stocks

Computer Integrated Systems Design Industry

4th out of 64 stocks

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Simulations Plus (NASDAQ:SLP) Frequently Asked Questions

Is Simulations Plus a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Simulations Plus in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Simulations Plus stock.
View analyst ratings for Simulations Plus
or view top-rated stocks.

What stocks does MarketBeat like better than Simulations Plus?

Wall Street analysts have given Simulations Plus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Simulations Plus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Simulations Plus' next earnings date?

Simulations Plus is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Simulations Plus
.

How were Simulations Plus' earnings last quarter?

Simulations Plus, Inc. (NASDAQ:SLP) posted its earnings results on Sunday, July, 11th. The technology company reported $0.18 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $0.18. The technology company had revenue of $12.78 million for the quarter, compared to the consensus estimate of $14.99 million. Simulations Plus had a net margin of 25.27% and a trailing twelve-month return on equity of 7.34%.
View Simulations Plus' earnings history
.

How has Simulations Plus' stock price been impacted by Coronavirus (COVID-19)?

Simulations Plus' stock was trading at $30.20 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SLP stock has increased by 57.0% and is now trading at $47.41.
View which stocks have been most impacted by COVID-19
.

How often does Simulations Plus pay dividends? What is the dividend yield for Simulations Plus?

Simulations Plus declared a quarterly dividend on Monday, July 12th. Stockholders of record on Monday, July 26th will be given a dividend of $0.06 per share on Monday, August 2nd. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date of this dividend is Friday, July 23rd.
View Simulations Plus' dividend history
.

Is Simulations Plus a good dividend stock?

Simulations Plus pays an annual dividend of $0.24 per share and currently has a dividend yield of 0.51%. Simulations Plus does not yet have a strong track record of dividend growth. The dividend payout ratio of Simulations Plus is 42.86%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Simulations Plus will have a dividend payout ratio of 38.71% next year. This indicates that Simulations Plus will be able to sustain or increase its dividend.
View Simulations Plus' dividend history.

What guidance has Simulations Plus issued on next quarter's earnings?

Simulations Plus issued an update on its FY 2021 earnings guidance on Tuesday, July, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $43.67 million-$45.75 million, compared to the consensus revenue estimate of $49.84 million.

What price target have analysts set for SLP?

4 brokers have issued 1 year target prices for Simulations Plus' shares. Their forecasts range from $54.00 to $76.00. On average, they expect Simulations Plus' share price to reach $67.50 in the next year. This suggests a possible upside of 42.4% from the stock's current price.
View analysts' price targets for Simulations Plus
or view top-rated stocks among Wall Street analysts.

Who are Simulations Plus' key executives?

Simulations Plus' management team includes the following people:
  • Mr. Walter S. Woltosz, Co-Founder & Chairman (Age 76, Pay $57.5k)
  • Mr. Shawn M. O'Connor, Chief Exec. Officer (Age 61, Pay $506k)
  • Mr. John Anthony DiBella, Pres of the Lancaster Division (Age 41, Pay $293.04k)
  • Mr. William Frederick, CFO & Sec. (Age 57)
  • Dr. Alexander Berg, VP of Operations
  • Ms. Viera Lukacova Ph.D., Chief Scientist
  • Ms. Arlene Padron, Marketing Director
  • Nguyen Nguyen, VP of HR
  • Dr. Michael B. Bolger Ph.D., Founding Scientist
  • Dr. Thaddeus Henry Grasela Jr., Pharm.D., PharmD, Ph.D., Exec. VP of Cognigen (Age 67)

Who are some of Simulations Plus' key competitors?

What other stocks do shareholders of Simulations Plus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Simulations Plus investors own include Advanced Micro Devices (AMD), Cisco Systems (CSCO), Gilead Sciences (GILD), QUALCOMM (QCOM), NVIDIA (NVDA), Verizon Communications (VZ), CVS Health (CVS), Enterprise Products Partners (EPD), AbbVie (ABBV) and Pfizer (PFE).

What is Simulations Plus' stock symbol?

Simulations Plus trades on the NASDAQ under the ticker symbol "SLP."

Who are Simulations Plus' major shareholders?

Simulations Plus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Prentiss Smith & Co. Inc. (0.18%) and State of Alaska Department of Revenue (0.05%). Company insiders that own Simulations Plus stock include David L Ralph, John Anthony Dibella II, John Kenneth Paglia, Lisa Lavange, Shawn Oconnor and Walter S Woltosz.
View institutional ownership trends for Simulations Plus
.

Which major investors are buying Simulations Plus stock?

SLP stock was acquired by a variety of institutional investors in the last quarter, including Prentiss Smith & Co. Inc., and State of Alaska Department of Revenue.
View insider buying and selling activity for Simulations Plus
or or view top insider-buying stocks.

How do I buy shares of Simulations Plus?

Shares of SLP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Simulations Plus' stock price today?

One share of SLP stock can currently be purchased for approximately $47.41.

How much money does Simulations Plus make?

Simulations Plus has a market capitalization of $954.36 million and generates $41.59 million in revenue each year. The technology company earns $9.33 million in net income (profit) each year or $0.56 on an earnings per share basis.

How many employees does Simulations Plus have?

Simulations Plus employs 129 workers across the globe.

What is Simulations Plus' official website?

The official website for Simulations Plus is www.simulations-plus.com.

Where are Simulations Plus' headquarters?

Simulations Plus is headquartered at 42505 10TH STREET WEST, LANCASTER CA, 93534.

How can I contact Simulations Plus?

Simulations Plus' mailing address is 42505 10TH STREET WEST, LANCASTER CA, 93534. The technology company can be reached via phone at 661-723-7723 or via email at [email protected]


This page was last updated on 7/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.